Resveratrol differentially regulates NAMPT and SIRT1 in hepatocarcinoma cells and primary human hepatocytes

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Schuster, Susanne ^a   Penke, Melanie ^a   Gorski, Theresa ^a   Petzold Quinque, Stefanie ^a   Damm, Georg ^b   Gebhardt, Rolf ^c   Kiess, Wieland ^a   Garten, Antje ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; MESSENGER RNA; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROTEIN P53; RESVERATROL; SIRTUIN 1; ANTINEOPLASTIC AGENT; CYTOKINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN; SIRT1 PROTEIN, HUMAN; STILBENE DERIVATIVE;

ACETYLATION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL CYCLE ARREST; CELL STRAIN HEP3B; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME RELEASE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LIVER CELL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; S PHASE CELL CYCLE CHECKPOINT; ANTIBODY SPECIFICITY; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CYTOKINES; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTES; HUMANS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; ORGAN SPECIFICITY; PRIMARY CELL CULTURE; RNA, MESSENGER; S PHASE CELL CYCLE CHECKPOINTS; SIGNAL TRANSDUCTION; SIRTUIN 1; STILBENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84897137060     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091045     Document Type: Article

References (74)

1. Bishayee A, Politis T, Darvesh AS (2010) Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat Rev 36: 43-53.
2. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220. (Pubitemid 127696281)
3. Delmas D, Lancon A, Colin D, Jannin B, Latruffe N (2006) Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr Drug Targets 7: 423-442. (Pubitemid 43744833)
4. Delmas D, Solary E, Latruffe N (2011) Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe. Curr Med Chem 18: 1100-1121.
5. Vang O, Ahmad N, Baile CA, Baur JA, Brown K, et al. (2011) What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One 6: e19881.
6. Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506. (Pubitemid 44136961)
7. Joe AK, Liu H, Suzui M, Vural ME, Xiao D, et al. (2002) Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res 8: 893-903. (Pubitemid 34742123)
8. Baarine M, Thandapilly SJ, Louis XL, Mazue F, Yu L, et al. (2011) Proapoptotic versus anti-apoptotic properties of dietary resveratrol on tumoral and normal cardiac cells. Genes Nutr 6: 161-169.
9. Kuo PL, Chiang LC, Lin CC (2002) Resveratrol- induced apoptosis is mediated by p53-dependent pathway in Hep G2 cells. Life Sci 72: 23-34.
10. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, et al. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196. (Pubitemid 37150899)
11. Frazzi R, Valli R, Tamagnini I, Casali B, Latruffe N, et al. (2012) Resveratrol-mediated apoptosis of hodgkin lymphoma cells involves SIRT1 inhibition and FOXO3a hyperacetylation. Int J Cancer.
12. Bjorklund M, Roos J, Gogvadze V, Shoshan M (2011) Resveratrol induces S. Cancer Chemother Pharmacol 68: 1459-1467.
13. Yang Q, Wang B, Zang W, Wang X, Liu Z, et al. (2013) Resveratrol inhibits the growth of gastric cancer by inducing g1 phase arrest and senescence in a sirt1-dependent manner. PLoS One 8: e70627.
14. Deng CX (2009) SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci 5: 147-152.
15. Liu T, Liu PY, Marshall GM (2009) The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 69: 1702-1705.
16. Vaziri H, Dessain SK, Ng EE, Imai SI, Frye RA, et al. (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149-159. (Pubitemid 33035942)
17. Zhang Q, Zeng SX, Zhang Y, Zhang Y, Ding D, et al. (2012) A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53. EMBO Mol Med 4: 298-312.
18. Bi TQ, Che XM (2010) Nampt/PBEF/visfatin and cancer. Cancer Biol Ther 10: 119-125.
19. Berger F, Ramirez-Hernandez MH, Ziegler M (2004) The new life of a centenarian: signalling functions of NAD(P). Trends Biochem Sci 29: 111-118. (Pubitemid 38314856)
20. Chiarugi A, Dolle C, Felici R, Ziegler M (2012) The NAD metabolome - a key determinant of cancer cell biology. Nat Rev Cancer 12: 741-752.
21. Houtkooper RH, Canto C, Wanders RJ, Auwerx J (2010) The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev 31: 194-223.
22. Revollo JR, Grimm AA, Imai S (2004) The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 279: 50754-50763. (Pubitemid 40017813)
23. Revollo JR, Grimm AA, Imai S (2007) The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 23: 164-170. (Pubitemid 46192971)
24. Zhang T, Berrocal JG, Frizzell KM, Gamble MJ, DuMond ME, et al. (2009) Enzymes in the NAD+ salvage pathway regulate SIRT1 activity at target gene promoters. J Biol Chem 284: 20408-20417.
25. Ho C, van d, V, Akawi O, Pickering JG (2009) SIRT1 markedly extends replicative lifespan if the NAD+ salvage pathway is enhanced. FEBS Lett 583: 3081-3085.
26. Hufton SE, Moerkerk PT, Brandwijk R, de Bruine AP, Arends JW, et al. (1999) A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett 463: 77-82. (Pubitemid 30001722)
27. Van Beijnum JR, Moerkerk PT, Gerbers AJ, de Bruine AP, Arends JW, et al. (2002) Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int J Cancer 101: 118-127. (Pubitemid 34970903)
28. Folgueira MA, Carraro DM, Brentani H, Patrao DF, Barbosa EM, et al. (2005) Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 11: 7434-7443. (Pubitemid 41507704)
29. Hasmann M, Schemainda I (2003) FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 63: 7436-7442. (Pubitemid 37413486)
30. Thakur BK, Dittrich T, Chandra P, Becker A, Kuehnau W, et al. (2013) Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells. Int J Cancer 132: 766-774.
31. Drevs J, Loser R, Rattel B, Esser N (2003) Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer Res 23: 4853-4858. (Pubitemid 38173905)
32. Muruganandham M, Alfieri AA, Matei C, Chen Y, Sukenick G, et al. (2005) Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Clin Cancer Res 11: 3503-3513. (Pubitemid 40627905)
33. Thakur BK, Dittrich T, Chandra P, Becker A, Lippka Y, et al. (2012) Inhibition of NAMPT pathway by FK866 activates the function of p53 in HEK293T cells. Biochem Biophys Res Commun 424: 371-377.
34. Solomon JM, Pasupuleti R, Xu L, McDonagh T, Curtis R, et al. (2006) Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol 26: 28-38.
35. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, et al. (2004) Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303: 2011-2015. (Pubitemid 38393275)
36. Nussler AK, Nussler NC, Merk V, Brulport M, Schormann W, et al. (2009) The Holy Grail of Hepatocyte Culturing and Therapeutic Use. In: Santin M, editors. Strategies in Regenerative Medicine. New York, USA. 283-320.
37. Peck B, Chen CY, Ho KK, Di Fruscia P, Myatt SS, et al. (2010) SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther 9: 844-855.
38. Elliott GC, Ajioka J, Okada CY (1980) A rapid procedure for assaying nicotinamide phosphoribosyltransferase. Anal Biochem 107: 199-205. (Pubitemid 11196643)
39. Ramsey KM, Yoshino J, Brace CS, Abrassart D, Kobayashi Y, et al. (2009) Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science 324: 651-654.
40. Chini CC, Gonzalez GA, Nin V, Camacho-Pereira J, Escande C, et al. (2013) Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors. Clin Cancer Res.
41. Cagnetta A, Cea M, Calimeri T, Acharya C, Fulciniti M, et al. (2013) Intracellular NAD(+) depletion enhances bortezomib-induced anti-myeloma activity. Blood 122: 1243-1255.
42. Tan B, Young DA, Lu ZH, Wang T, Meier TI, et al. (2013) Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications. J Biol Chem 288: 3500-3511.
43. Garten A, Petzold S, Barnikol-Oettler A, Korner A, Thasler WE, et al. (2010) Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem Biophys Res Commun 391: 376-381.
44. Delmas D, Jannin B, Cherkaoui MM, Latruffe N (2000) Inhibitory effect of resveratrol on the proliferation of human and rat hepatic derived cell lines. Oncol Rep 7: 847-852.
45. De L, V, Monvoisin A, Neaud V, Krisa S, Payrastre B, et al. (2001) Transresveratrol, a grapevine-derived polyphenol, blocks hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells. Int J Oncol 19: 83-88.
46. Carbo N, Costelli P, Baccino FM, Lopez-Soriano FJ, Argiles JM (1999) Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. Biochem Biophys Res Commun 254: 739-743. (Pubitemid 29290538)
47. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, et al. (2004) Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24: 2783-2840. (Pubitemid 39409568)
48. Venturelli S, Berger A, Bocker A, Busch C, Weiland T, et al. (2013) Resveratrol as a pan-HDAC inhibitor alters the acetylation status of jistone proteins in human-derived hepatoblastoma cells. PLoS One 8: e73097.
49. Mahyar-Roemer M, Katsen A, Mestres P, Roemer K (2001) Resveratrol induces colon tumor cell apoptosis independently of p53 and precede by epithelial differentiation, mitochondrial proliferation and membrane potential collapse. Int J Cancer 94: 615-622. (Pubitemid 33035679)
50. Gogada R, Prabhu V, Amadori M, Scott R, Hashmi S, et al. (2011) Resveratrol induces p53-independent, X-linked inhibitor of apoptosis protein (XIAP)-mediated Bax protein oligomerization on mitochondria to initiate cytochrome c release and caspase activation. J Biol Chem 286: 28749-28760.
51. Bernhard D, Tinhofer I, Tonko M, Hubl H, Ausserlechner MJ, et al. (2000) Resveratrol causes arrest in the S-phase prior to Fas-independent apoptosis in CEM-C7H2 acute leukemia cells. Cell Death Differ 7: 834-842.
52. Zhou R, Fukui M, Choi HJ, Zhu BT (2009) Induction of a reversible, noncytotoxic S-phase delay by resveratrol: implications for a mechanism of lifespan prolongation and cancer protection. Br J Pharmacol 158: 462-474.
53. Chen J, Zhang B, Wong N, Lo AW, To KF, et al. (2011) Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer Res 71: 4138-4149.
54. Chen HC, Jeng YM, Yuan RH, Hsu HC, Chen YL (2012) SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis. Ann Surg Oncol 19: 2011-2019.
55. Wang H, Liu H, Chen K, Xiao J, He K, et al. (2012) SIRT1 promotes tumorigenesis of hepatocellular carcinoma through PI3K/PTEN/AKT signaling. Oncol Rep 28: 311-318.
56. Portmann S, Fahrner R, Lechleiter A, Keogh A, Overney S, et al. (2013) Antitumor effect of SIRT1 inhibition in human HCC tumor models in vitro and in vivo. Mol Cancer Ther 12: 499-508.
57. Zhang C, Feng Y, Qu S, Wei X, Zhu H, et al. (2011) Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc Res 90: 538-545.
58. Wang RH, Zheng Y, Kim HS, Xu X, Cao L, et al. (2008) Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell 32: 11-20.
59. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342. (Pubitemid 44764104)
60. Kaeberlein M, McDonagh T, Heltweg B, Hixon J, Westman EA, et al. (2005) Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 280: 17038-17045. (Pubitemid 41389166)
61. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, et al. (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285: 8340-8351.
62. Hu Y, Liu J, Wang J, Liu Q (2011) The controversial links among calorie restriction, SIRT1, and resveratrol. Free Radic Biol Med 51: 250-256.
63. Beher D, Wu J, Cumine S, Kim KW, Lu SC, et al. (2009) Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 74: 619-624.
64. Pizarro JG, Verdaguer E, Ancrenaz V, Junyent F, Sureda F, et al. (2011) Resveratrol inhibits proliferation and promotes apoptosis of neuroblastoma cells: role of sirtuin 1. Neurochem Res 36: 187-194.
65. Kai L, Samuel SK, Levenson AS (2010) Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. Int J Cancer 126: 1538-1548.
66. Dixit D, Sharma V, Ghosh S, Mehta VS, Sen E (2012) Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFalpha)-induced apoptosis through SIRT1 inhibition. Cell Death Dis 3: e271.
67. Flick F, Luscher B (2012) Regulation of sirtuin function by posttranslational modifications. Front Pharmacol 3: 29.
68. Kang H, Jung JW, Kim MK, Chung JH (2009) CK2 is the regulator of SIRT1 substrate-binding affinity, deacetylase activity and cellular response to DNA-damage. PLoS One 4: e6611.
69. Whitlock NC, Baek SJ (2012) The anticancer effects of resveratrol: modulation of transcription factors. Nutr Cancer 64: 493-502.
70. Kover K, Tong PY, Watkins D, Clements M, Stehno-Bittel L, et al. (2013) Expression and regulation of nampt in human islets. PLoS One 8: e58767.
71. Samal B, Sun Y, Stearns G, Xie C, Suggs S, et al. (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14: 1431-1437.
72. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, et al. (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307: 426-430. (Pubitemid 40139988)
73. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, et al. (2007) Retraction. Science 318: 565.
74. Revollo JR, Korner A, Mills KF, Satoh A, Wang T, et al. (2007) Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 6: 363-375. (Pubitemid 350011996)